investor motivation podcast

Investment Deep Dive: LVMH (Louis Vuitton Moët Hennessy)

In the fourth episode of our new series on the Investment Motivation podcast, Rob Goudie and Rachael Todman take a deep dive into LVMH, the world’s leading luxury goods company.

They explore what makes LVMH unique, from its diverse portfolio of iconic brands like Louis Vuitton and Moët & Chandon to its recent financial performance, growth prospects, dividend policies, and analyst valuations.

Rob and Rachael also highlight the ownership structure, led by Bernard Arnault and his family’s significant stake, and provide insights into the latest news impacting the luxury giant.

Don’t miss this comprehensive breakdown of what drives LVMH’s market success and potential future challenges.

Please Note: This is not a buy, nor sell, recommendation. This is general information only.

Robert Goudie, CFP, GradDipFP (ASIC Reg 235974) and Amy Lehmann, BBus (FinPlan), BBus (Acc) (ASIC Reg 1292710), are authorised representatives of Consortium Private Wealth Pty Ltd | ABN 74 616 250 965 AFS Licence 495401. 

Similar Posts

  • Smart investing: Strategies for 1K, 5K & 50K budgets

    Join us as we explore practical investment strategies for budgets ranging from $1,000 to $50,000. Whether you’re a beginner or seasoned investor, we offer actionable advice on fund allocation and…

  • Aged Care Decisions That Impact Families

    In this episode , Rob Goudie is joined by long-term advisor and partner Ash to discuss real-world aged care case studies and the financial decisions that impact families. They unpack…

  • How to be great with money!

    Join us as we explore the essential elements of effective money management, offering insights into building a secure future. From spending wisely and creating financial safety nets to making strategic…

  • Investment Deep Dive: CSL Ltd (ASX: CSL)

    In this episode, we analyse CSL Limited (ASX: CSL), a $134 billion market cap biotechnology company specialising in plasma-derived therapies, vaccines, and rare disease treatments. Operating in over 100 countries…